![]() A Sri Lankan woman is vaccinated in 2021 as part of the COVAX initiative | |
Date | 29 January 2021 – present |
---|---|
Location | Sri Lanka |
Cause | COVID-19 pandemic in Sri Lanka |
Organized by | Government of Sri Lanka |
Outcome |
|
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. [1] The United States donated over 1.5 million Moderna vaccine through COVAX. [2]
The Government of Sri Lanka commenced its COVID-19 vaccination program under the COVAX facility with first batch of Oxford–AstraZeneca vaccines arrive in Sri Lanka on 28 January 2021 from the Serum Institute of India. (SII). [3]
By April, with a surge in COVID cases in a third wave of infections, Sri Lanka faced a severe shortage of the Astra-Zeneca vaccine due to an export ban by India. [4] This left majority of the 3.5% of the population that was given the first dose without access to the second. [5] Sri Lanka faced an shortage of Sputnik V vaccine due to a spike of cases in Russia resulting in the manufacturer Gamaleya Research Institute of Epidemiology and Microbiology, focusing on meeting local demand. [6]
In March 2021, the Sinopharm BIBP vaccine was approved emergency use. [7] In May, the country ordered 14 million doses on top of 1.1 million doses previously donated. [8] By July, Sri Lanka had received 10.7 million doses of the vaccine. [1] In June, local studies in the country showed vaccination with the Sinopharm BIBP vaccine generated seroconversion and antibody responses in individuals to Delta and Beta variants similar to antibody levels seen following a natural infection [9] [10]
With vaccination of persons above 30 years reaching completion, vaccination of those between 18 and 30 years who did not fall under special categories were started in early September 2021. [11]
On 27 May State Minister for Pharmaceuticals Channa Jayasumana told reporters Sri Lanka was considering co-production of CoronaVac. It was not clarified if it would handle full production or a fill and finish plant. [12]
Currently, the vaccines approved by government of Sri Lanka for emergency use are:
Vaccine | Approval | Deployment |
---|---|---|
Oxford–AstraZeneca | ![]() | ![]() |
Sinopharm BIBP | ![]() | ![]() |
Sputnik V | ![]() | ![]() |
Pfizer–BioNTech | ![]() | ![]() |
Moderna | ![]() | ![]() |
Sinovac | ![]() | ![]() |
Vaccine types were deployed on a geographical and group basis:
Vaccine | Type (technology) | Doses ordered | Manufacturer | Remarks |
---|---|---|---|---|
Oxford–AstraZeneca | Viral vector | 8,400,000 | ![]() | - |
Sputnik V | Viral vector | 13,000,000 | ![]() | - |
Pfizer–BioNTech | RNA | 14,900,000 [15] [11] | ![]() | - |
Sinopharm BIBP | Inactivated virus | 23,000,000 [16] [8] | ![]() | - |